Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone plus ECT for persistent methamphetamine-induced psychosis
IRCT20130812014333N101Phase 3Completed
- Sponsor
- Kermanshah University of Medical Sciences
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of risperidone in stimulant-induced psychosis (2 arms), sponsored by Kermanshah University of Medical Sciences. Primary endpoint: Severity of psychotic symptoms. Started Sep 2018; status: completed.
02
Drugs
risperidone
03
Conditions
stimulant-induced psychosis
Beyond the preview
Go deeper on IRCT20130812014333N101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130812014333N101.